Solifenacin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Solifenacin
- Solifenacin: From Overactive Bladder to Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease)
Solifenacin: From Overactive Bladder to Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease)
One-Sentence Summary
Solifenacin is a selective M3 muscarinic receptor antagonist established for overactive bladder (OAB), identified from the literature within this evidence pack (no South African product-label text is available, as the drug is not currently marketed here). The TxGNN model’s top-ranked prediction is that it may be effective for Polycystic Kidney Disease 3, with or without Polycystic Liver Disease, but this ranking is supported by 0 clinical trials and 20 publications that describe the disease itself, not solifenacin’s use in it — the evidence pack’s own analysis flags this as a likely knowledge-graph topology artefact rather than a genuine pharmacological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Overactive bladder (OAB) — identified from literature within this evidence pack; no South African/SAHPRA product-label text available (see Market Status below) |
| Predicted New Indication | Polycystic Kidney Disease 3, with or without Polycystic Liver Disease |
| TxGNN Prediction Score | 97.13% |
| Evidence Level | L4 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for solifenacin is not available in this evidence pack (flagged internally as a High-severity data gap, DG002). Based on generally established pharmacology, solifenacin is a selective M3 muscarinic receptor antagonist that relaxes detrusor smooth muscle, which is the basis of its use in overactive bladder.
Polycystic Kidney Disease 3 (with or without polycystic liver disease) is a genetic ciliopathy in which cyst growth is driven by cAMP-dependent signalling in renal tubular and cholangiocyte epithelium — a pathway unrelated to bladder detrusor contractility. None of the 20 literature results returned for this pairing discuss solifenacin, muscarinic antagonism, or cAMP-cystogenesis; they are disease-overview reviews and guidelines about PKD/PLD genetics, diagnosis, and management (e.g., ADPKD genetics, EASL cystic liver disease guidelines).
The evidence pack’s own rationale is explicit on this point: the high TxGNN score most likely reflects the topological proximity of urinary- and renal-system nodes in the knowledge graph, rather than a real pharmacological relationship. This mechanistic implausibility, combined with the complete absence of drug-specific trials or literature, is why this candidate is scored L4 and recommended for Hold rather than active development.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38958301 | 2024 | Guideline | Am J Gastroenterol | ACG guideline on focal liver lesions, including management of polycystic liver disease; does not discuss solifenacin |
| 30819518 | 2019 | Review | Lancet | Overview of ADPKD genetics, clinical manifestations (renal cysts, liver cysts, hypertension); no drug-therapy discussion relevant to solifenacin |
| 35487607 | 2022 | Review | Clin Liver Dis | ADPKD/PCLD clinical course; notes tolvaptan (a vasopressin-receptor antagonist, not solifenacin) as an approved ADPKD therapy |
| 29038287 | 2018 | Review | J Am Soc Nephrol | Genetic complexity and causative genes (PKD1, PKD2, PRKCSH, SEC63, GANAB) of ADPKD/ADPLD |
| 38097330 | 2023 | Review | Adv Kidney Dis Health | Genetic spectrum and phenotypes of polycystic kidney and liver disease |
| 35728731 | 2022 | Clinical Practice Guideline | J Hepatol | EASL guideline on diagnosis and management of cystic liver diseases |
| 28375157 | 2017 | Genetic study | J Clin Invest | Whole-exome sequencing identifying isolated PCLD genes and polycystin-1 pathway effectors |
| 34034501 | 2022 | Review | Rev Esp Enferm Dig | Diagnosis and management of hepatic hydatid cyst (a differential diagnosis, not PKD/PLD treatment) |
| 36047551 | 2022 | Review | Rev Med Suisse | Overview of polycystic liver disease subtypes and clinical course |
| 37266470 | 2023 | Case report | Maedica | Case of ADPKD/polycystic liver disease co-occurring with gastric cancer |
None of the above publications evaluate solifenacin, and none support a treatment rationale for this indication.
South Africa Market Information
Solifenacin is currently not marketed in South Africa: 0 SAHPRA registrations are on record in this evidence pack, so no registered product name, dosage form, or approved-indication text is available for South Africa.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(Note: retrieval of TFDA/SAHPRA-equivalent label warnings and contraindications is flagged internally as a Blocking data gap — this must be resolved before any safety pre-assessment can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The 97.13% TxGNN score for Polycystic Kidney Disease 3 is not supported by any drug-specific clinical trial or literature evidence; the pack’s own analysis attributes the score to knowledge-graph topological proximity rather than a plausible pharmacological mechanism.
- Separately, this same evidence pack contains a substantially stronger candidate for solifenacin repurposing — “low compliance bladder” (rank 7), evidence level L2, with a Phase 4 trial and multiple RCTs directly evaluating antimuscarinic therapy (including solifenacin) for neurogenic/low-compliance bladder, a mechanistically direct extension of its OAB indication, scored “Proceed with Guardrails.” That candidate merits prioritized review ahead of this one.
To proceed, the following is needed:
- Preclinical or mechanistic evidence directly linking M3 muscarinic antagonism to cAMP-driven cystogenesis in PKD3/PLD before this candidate can be re-scored above L4
- SAHPRA-equivalent Professional Information (PI) — warnings and contraindications (Blocking gap, DG001)
- Confirmed original indication and mechanism-of-action documentation for solifenacin (DG002)
- Verification of South Africa registration status, given 0 SAHPRA licenses are currently on record
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.